Barrett’s Esophagus: Pathogenesis, Treatment, and Prevention - 22/08/11
Doi : 10.1016/j.giec.2008.05.005
Rami J. Badreddine, MD, Kenneth K. Wang, MD ⁎ 
Barrett’s Esophagus Unit, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
Corresponding author. Barrett’s Esophagus Unit, Alfred Main, Gastroenterology Diagnostic Unit, St. Mary’s Hospital, 200 1st Street SW, Rochester, MN 55905.Abstract |
Esophageal adenocarcinoma is the most common type of esophageal cancer seen in the United States and Western Europe. Barrett's esophagus (BE) is a well-known risk factor for esophageal adenocarcinoma and is believed to be found in 6% to 12% of patients undergoing endoscopy for gastroesophageal reflux disease and in more than 1% of all patients undergoing endoscopy. This article focuses on the pathogenesis, treatment, and prevention of BE.
Le texte complet de cet article est disponible en PDF.Plan
| Supported by NIH Grants R01 CA111603-01A1, R01CA097048, and R21CA122426-01. |
© 2008
Publié par Elsevier Masson SAS.
Vol 18 - N° 3
P. 495-512 - juillet 2008 Retour au numéro
Article précédent
- Positron Emission Tomography for the Diagnosis and Management of Patients with Gastrointestinal Malignancies
- Tsuneo Saga, Yuji Nakamoto, Tatsuya Higashi, Kyosan Yoshikawa
- Gastric Cancer: Pathogenesis, Screening, and Treatment
- Kentaro Sugano
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?